Hi All,I recently reached out to Echo IQ’s Chief Commercial Officer, Deon Strydom, for some clarification on a few items, and I’d like to share the highlights of our conversation.
Competitive Advantage: Echo IQ’s AI is trained exclusively on numerical data for echocardiogram analysis, unlike competitors that focus on image-based AI, resulting in faster processing times. Ultromics and iCardio use predominantly images for their Ai component, Ultromics takes 1/2 to process images, whereas EchoIQ takes 3 seconds to process data.
Risk Communication: Echo IQ will communicate material updates, including any delays, via quarterly ASX reports. Non-material events, such as staff turnover of non-key roles, are not typically reported. If there is anything specific a shareholder would like to ask during these meetings the company will gladly respond. US Echocardiogram Volume: Echo IQ estimates around 20 million echocardiograms annually, factoring in both Medicare and private insurance.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)